This retrospective study using real-world data was intended to affirm a mechanistic hypothesis, and not to yield a definitive conclusion as to whether Nrf2 activation provides additional metabolic disease benefit in patients with MS. The gene discussed is NFE2L2; the disease is metabolic disease.